Background and Purpose-Little is known about the development of cerebral microbleeds in patients with ischemic stroke. We studied the incidence of new microbleeds in a cohort of patients with ischemic stroke or transient ischemic attack screened for microbleeds at baseline. Methods-Twenty-one surviving patients with ischemic stroke or transient ischemic attack were followed up after a mean interval of 5.5 years with repeat MRI and clinical assessment. Predictors of new microbleeds were tested in logistic regression. Results-Of patients with microbleeds at baseline, 50% had new microbleeds at follow-up compared with 8% of those without baseline microbleeds (Pϭ0.047). 
B
rain microbleeds seen on gradient-recalled echo T2*-weighted MRI, are increasingly detected in patients with ischemic stroke (IS). 1 Microbleeds are a radiological correlate of small hemorrhages adjacent to small vessels affected by cerebral amyloid angiopathy or hypertensive arteriopathy. 2 In cerebral amyloid angiopathy, microbleeds accumulate over time and predict clinical decline and larger bleeds. 3, 4 Little is known about microbleed development over time in patients with IS, although they may have cumulative effects on brain function, including cognition. 5 We assessed new microbleeds in patients with IS or transient ischemic attack after 5.5 years of follow-up. We hypothesized that baseline microbleeds and higher blood pressure (BP) increase the risk of developing new microbleeds.
Methods
Consecutive individuals referred to the National Hospital for Neurology and Neurosurgery neurovascular clinic underwent clinical assessment and gradient-recalled echo T2*-weighted MRI. Twentyfive patients with microbleeds and a microbleed-free group (Nϭ30) matched for clinical and radiological characteristics were selected as described previously. 5 Patients with confirmed IS or transient ischemic attack (Nϭ48) were invited for repeat MRI and clinical assessment. All baseline and follow-up MRIs were carried out on a GE Medical Genesis Signa 1.5-T system using a standardized protocol. 5 Images were assessed by S.M.G. blinded to clinical details using validated rating scales for white matter changes 6 and microbleeds. 7 Statistical analysis was performed using SPSS Version 16.0 and Stata Version 10.0. The study was approved by our research ethics committee. All participants gave written informed consent.
Results
Of the original cohort (Nϭ48:Nϭ21 with microbleeds; Nϭ27 microbleed-free) 11 patients (23%, Nϭ7 with microbleeds [33%]; Nϭ4 microbleed-free [15%]; Pϭ0.164) died between original study enrollment and follow-up. The only vascular death was a myocardial infarction in the microbleed group. Four patients (8%) were lost to follow-up. Of the remaining 33 patients, a final cohort of 21 patients (64%, Nϭ8 with, Nϭ13 without microbleeds) underwent repeat MRI and clinical assessment ( Table 1 ). The mean interval between assessments was 5.6 years (SDϭ0.44).
At baseline, 8 patients had a total of 62 microhemorrhages (87% lobar, median 4.0, range 1 to 36; Table 2 
020).
We found no association between antiplatelet use, presence or number of lacunar infarcts, and new microbleeds.
The only vascular events were one intracerebral hemorrhage not at a microbleed site (microbleed group) and one nonfatal myocardial infarction (microbleed-free group).
Discussion
In this study, 50% of surviving patients with microbleeds at baseline developed new microbleeds over 5.6 years compared with only 8% of matched microbleed-free patients. The presence of microbleeds at baseline predicted new microbleed development. No similar data are available in IS cohorts, but in patients with cerebral amyloid angiopathy, the development of microbleeds was related to baseline microbleed number 4 and white matter changes. 8 Hypertension is an established risk factor for microbleeds in cross-sectional studies, 9 but we are not aware of longitudinal data on whether hypertension increases the risk of developing new microbleeds. We found that baseline systolic BP predicted the development of new microbleeds and was above 150 mm Hg in all patients in whom new microbleeds developed. Therefore, rigorous BP control in patients with IS with microbleeds may prevent the progression of small vessel damage and new microbleed formation. Many new microbleeds were detected despite patients remaining clinically stable, suggesting that the rate of microbleed accumulation may exceed that of clinical vascular events; microbleeds in patients with IS may therefore be a useful quantitative marker for progression of small vessel pathology.
Most microbleeds detected at baseline were lobar as were all new microbleeds. Although lobar microbleeds are suggested to reflect cerebral amyloid angiopathy, whereas deep microbleeds are due to hypertensive arteriopathy, the 2 pathologies may interact or coexist. 2 In our study, patients with deep microbleeds were overrepresented in patients who died or were lost to follow-up, which may have introduced bias toward detecting new lobar microbleeds.
The main limitation of our study is the small sample size. However, the overall prevalence of microbleeds in patients with IS in our neurovascular clinic is 23%, 1 in line with other estimates, 10 suggesting that our findings are generalizable. We used one-off BP measurements so we could not relate microbleed accumulation to control of BP during follow-up. It is possible that some apparently new microbleeds resulted from head movement between scans; however, this is unlikely because we did not find a significant number of "disappearing" microbleeds at follow-up.
Cerebral microbleeds may be useful for objectively monitoring the progression of small vessel pathology in patients with IS in observational or therapeutic studies. Larger prospective studies are needed to determine whether specific treatments (eg, aggressive hypertension treatment) can reduce microbleed formation and how microbleed accumulation relates to long-term clinical outcomes. and David J. Werring
